The following listing of claims set forth replace all prior versions and listings of claims in the application.

IN THE CLAIMS

1. (currently amended) A compound of Formula I :



Formula I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is $N(CH_3)$ or O;

R_1 is OH or C_{1-6} alkoxy;

R_2 is H or C_{1-6} alkyl;

R_3 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl, ~~phenyl,~~ or furanyl~~, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl , cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl~~, and

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2; and

R_4 is H or C_{1-6} alkyl~~; or~~

~~R_3 and R_4 together with the nitrogen atom to which R_3 and R_4 are attached, form 1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridyl, or 8-aza-bicyclo[3.2.1.]octane, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_m$Z,~~

~~Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and~~

PAGE 3/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

~~Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6}alkyl, C_{1-6}alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and~~

~~m is 0 or 1;~~

~~provided that when R_1 is OH, R_2 is H:~~

~~(1) R_4 is H, and R_3 is $(CH_2)_nQ$, where n is 1 or 2, then Q cannot be indolyl or phenyl; or~~

~~(2) R_3 and R_4 form piperazinyl substituted with $(CH_2)_mZ$, when m is 1, then Z cannot be phenyl.~~

2. (currently amended) A compound according to claim 1 wherein
Q is thienyl ~~or pyridyl;~~
~~or R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form piperidinyl.~~

3. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-[thienophen-2-ylmethyl)-amino-propan-2-ol.

4. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-3-ylmethyl)-amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

5. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-2-ylmethyl)-amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

6. (withdrawn) The compound according to claim 2 which is (2S)-1-(2-thienylmethylamino)-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

7. (withdrawn) The compound according to claim 2 which is (2S)-1-[4-(3-chlorophenoxy)-1-piperidinyl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

8. (withdrawn) The compound according to claim 2 which is (2S)-1-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)piperidin-1-yl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

9. (withdrawn) The compound according to claim 2 which is (2R)-2-methyl-1-[(pyridin-4-ylmethyl)-amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

10. (withdrawn) The compound according to claim 2 which is (2R)-1-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)piperidin-1-yl]-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

11. (withdrawn) The compound according to claim 2 which is (2S)-1-(3-thienylmethylamino)-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

12. (withdrawn) The compound according to claim 2 which is (2S)-2-methyl-1-[(pyridin-3-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

PAGE 4/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

13. (withdrawn) The compound according to claim 2 which is (2S)-2-methyl-1-[(pyridin-2-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

14. (withdrawn) The compound according to claim 2 which is (4-fluorophenyl)-(1-{2(R)-hydroxy-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy]-propyl}-piperidin-4-yl)-methanone.

15. (withdrawn) The compound according to claim 2 which is 1-(1-{2(R)-hydroxy-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy]-propyl}-piperidin-4-yl)-1,3-dihydrobenzimidazol-2-one.

16. (withdrawn) A compound according to claim 2 wherein

R_1 is OH;

R_2 is H;

R_3 is $(CH_2)_n$ Q; or

R_3 and R_4 together with the nitrogen atom to which R_3 and R_4 are attached form piperidinyl; and

n is 1.

17. (original) A compound according to claim 16 wherein Q is thienyl.

18. (original) The compound according to claim 17 which is (2R)-1-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)-amino]-propan-2-ol.

19. (original) The compound of claim 17 which is (2R)-1-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)-amino]-propan-2-ol.

20. (original) The compound of claim 17 which is (2R)-1-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-[(thiophen-2-ylmethyl)amino]propan-2-ol.

21. (original) The compound of claim 17 which is (2R)-1-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-[(thiophen-3-ylmethyl)amino]propan-2-ol.

22. (withdrawn) A compound according to claim 16 wherein Q is pyridyl.

23. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-4-yl)methylamino]-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

24. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-2-ylmethyl)-amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

25. (withdrawn) The compound of claim 22 which is (2R)-1-[(pyridin-3-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

26. (withdrawn) A compound according to claim 16 wherein R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form piperidinyl.

27. (withdrawn) The compound according to claim 26 which is 4-(4-chlorophenyl)-1-{(R)2-hydroxy-3-[3-(thieno[2,3-d]isoxazol-3-yl)phenoxy]propyl}piperidin-4-ol.

PAGE 5/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

28. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-fluorobenzo[*d*]isoxazol-3-yl)piperidin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

29. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-chlorobenzo[*d*]isoxazol-3-yl)piperidin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

30. (withdrawn) The compound of claim 26 which is (2R)-1-[4-(6-fluorobenzo[*d*]isothiazol-3-yl)-piperdin-1-yl]-3-(thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

31. (withdrawn) The compound of claim 26 which is (2R)-1-(4-benzylpiperidin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

32. (withdrawn)The compound of claim 26 which is (2R)-1-piperidin-1-yl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

33. (withdrawn) A compound according to claim 1 wherein
R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form piperazinyl.

34. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-chlorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

35. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-methoxyphenyl)-piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

36. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-fluorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

37. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-fluorophenyl)piperzain-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

38. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-chlorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

39. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(3-chlorophenyl)piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

40. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-methoxyphenyl)piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

41. (withdrawn) The compound of claim 33 which is (2R)-1-(4-phenylpiperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

42. (withdrawn) The compound of claim 33 which is 2-{4-[(R)-2-hydroxy-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propyl]piperazin-1-yl}benzonitrile.

43. (withdrawn) The compound of claim 33 which is (2R)-1-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-[4-(2-trifluoromethylphenyl)-piperazin-1-yl]propan-2-ol.

44. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

45. (withdrawn) The compound of claim 33 which is 2-{4-[(R)-2-hydroxy-3-(4-thieno[2,3-d]isoxazol-3-yl-phenoxy)propyl]-piperazin-1-yl}benzonitrile.

PAGE 6/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

46. (withdrawn) The compound of claim 33 which is (2S)-1-[4-(2-methoxyphenyl)piperazin-1-yl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

47. (withdrawn) The compound of claim 33 which is (2S)-1-[4-(2-cyanophenyl)-1-piperazinyl]-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

48. (withdrawn) The compound of claim 33 which is (2R)-1-(4-pyrimidin-2-yl-piperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

49. (withdrawn) The compound of claim 33 which is (2R)-1-(4-pyridin-2-yl-piperazin-1-yl)-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)-propan-2-ol.

50. (withdrawn) The compound of claim 33 which is (2R)-1-(4-benzo[1,3]dioxol-5-ylmethyl-piperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

51. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(6-fluoro-1H-indazol-3-yl)-piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

52. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(5-methoxy-1H-indazol-3-yl)-piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

53. (withdrawn) The compound of claim 33 which is (2R)-1-(4-benzo[*d*]isothiazol-3-yl-piperazin-1-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

54. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(6-fluorobenzo[b]thiophen-3-yl)piperazin-1-yl]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

55. (withdrawn) The compound of claim 33 which is 3-{(R)-4-[2-hydroxy-3(3-thieno[2,3-d]isoxazol-3-yl)phenoxy]propyl]-piperazin-1-yl}-benzo[d]isoxazol-6-ol.

56. (withdrawn) The compound of claim 33 which is (2R)-1-[4-(4-methoxyphenyl)-3-methylpiperazin-1-yl]-3-[3-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.

57. (withdrawn) The compound of claim 33 which is (2R)-1-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy-3-(4-phenyl-piperazin-1-yl)-propan-2-ol.

58. (withdrawn) The compound of claim 33 which is (2R)-1-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy-3-(4-pyrimidin-2-yl-piperazin-1-yl)-propan-2-ol.

59. (withdrawn) A compound according to claim 1 wherein Q is phenyl.

60. (withdrawn) The compound of claim 59 which is (2R)-1-(4-chlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

61. (withdrawn) The compound of claim 59 which is (2R)-1-[(N-benzyl-N-methyl)amino]-3-[2-thieno[2,3-*d*]isoxazol-3-yl)phenoxy]-2-propanol.

62. (withdrawn) The compound of claim 59 which is (2S)-(+)-1-benzylamino-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

63. (withdrawn) The compound of claim 59 which is (2R)-(-)-1-benzylamino-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

PAGE 7/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

64. (withdrawn) The compound of claim 59 which is (2R)-1-(benzylmethylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

65. (withdrawn) The compound of claim 59 which is (2R)-1-(4-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

66. (withdrawn) The compound of claim 59 which is (2R)-1-(4-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

67. (withdrawn) The compound of claim 59 which is (2R)-1-(2-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

68. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-3-(4-trifluoromethylbenzylamino)-propan-2-ol.

69. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-[1(R)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol]-3-yl-phenoxy)-propan-2-ol.

70. (withdrawn) The compound of claim 59 which is (2R)-2-methyl-1-[1(S)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol]-3-yl-phenoxy)-propan-2-ol.

71. (withdrawn) The compound of claim 59 which is (2R)-1-(2-hydroxy-2-phenylethylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

72. (withdrawn) The compound of claim 59 which is (2R)-benzyl-[2-methoxy-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propyl]-methylamine hydrochloride.

73. (withdrawn) The compound of claim 59 which is (2R)-benzyl-[2-methoxy-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propyl]-amine.

74. (withdrawn)The compound of claim 59 which is (2S)-1-(4-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

75. (withdrawn) The compound of claim 59 which is (2S)-1-(2-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

76. (withdrawn) The compound of claim 59 which is (2S)-1-(3-fluorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

77. (withdrawn) The compound of claim 59 which is (2S)-1-(4-chlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

78. (withdrawn) The compound of claim 59 which is (2S)-1-(2-chlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

79. (withdrawn) The compound of claim 59 which is (2S)-1-(3,4-dichlorobenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

80. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-[1(R)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol]-3-yl-phenoxy)-propan-2-ol.

81. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-[1(S)-phenylethylamino]-3-(3-thieno[2,3-*d*]isoxazol]-3-yl-phenoxy)-propan-2-ol.

PAGE 8/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

82. (withdrawn) The compound of claim 59 which is (2S)-2-methyl-1-(4-methylbenzylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

83. (withdrawn) The compound of claim 59 which is (2S)-1-(4-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

84. (withdrawn) The compound of claim 59 which is (2S)-1-(2-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

85. (withdrawn) The compound of claim 59 which is (2S)-1-(benzylmethylamino)-2-methyl-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

86. (withdrawn) The compound of claim 59 which is (2S)-1-(3,4-difluorobenzylamino)-2-methyl-3-[3-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.

87. (withdrawn) The compound of claim 59 which is (2R)-1-(2-methoxybenzylamino)-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

88. (original) A compound according to claim 1 wherein Q is furanyl.

89. (original) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)-amino]-2-methyl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

90. (original) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

91. (original) The compound of claim 88 which is (2R)-1-[(furan-2-ylmethyl)-amino]-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

92. (original) The compound of claim 88 which is (2S)-1-[(furan-2-ylmethyl)amino]-2-methyl-3-(3-thieno[2,3-d]isoxazol-3-yl-phenoxy)propan-2-ol.

93. (original) A compound according to claim 1 wherein R_3 is indanyl.

94. (original) The compound of claim 93 which is (2R)-1-(indan-1-ylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

95. (original) The compound of claim 93 which is (2R)-1-(indan-2-ylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

96. (withdrawn) A compound according to claim 1 wherein Q is naphthyl.

97. (withdrawn) The compound of claim 96 which is (2R)-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

98. (withdrawn) The compound of claim 96 which is (2R)-2-methyl-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

99. (withdrawn) The compound of claim 96 which is (2R)-1-[(naphthalen-1-ylmethyl)-amino]-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

100. (withdrawn) The compound of claim 96 which is (2S)-2-methyl-1-[(naphthalen-1-ylmethyl)amino]-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

PAGE 9/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

101. (withdrawn) A compound according to claim 1 wherein R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form 1,2,3,4-tetrahydroisoquinolinyl.

102. (withdrawn) The compound of claim 101 which is is (±)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[2-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]-2-propanol.

103. (withdrawn) The compound of claim 101 which is (2R)-1-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl]-3-[3-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.

104. (withdrawn) The compound of claim 101 which is (2R)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[2-(thieno[2,3-*d*]isoxazol-3-yl)phenoxy]-2-propanol.

105. (withdrawn) The compound of claim 101 which is (2R)-1-(3,4-dihydro-1H-isoquinolin-2-yl)-3-[3-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-phenoxy]-propan-2-ol.

106. (withdrawn) A compound according to claim 1, wherein R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form 1,2,3,4-tetrahydro-β-carbolinyl.

107. (withdrawn) The compound of claim 106 which is (2R)-1-(1,2,3,4-tetrahydro-β-carbolin-2-yl)-3-[3-thieno[2,3-*d*]isoxazol-3-yl)phenoxy]propan-2-ol.

108. (withdrawn) A compound according to claim 1, wherein R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form 4,5,6,7-tetrahydrothieno[3,2-c]pyridinyl.

109. (withdrawn) The compound of claim 108 which is (2R)-1-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

110. (withdrawn) The compound of claim 108 which is (2R)-1-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-3-(4-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

111. (withdrawn) A compound according to claim 1, wherein R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form 8-aza-bicyclo[3.2.1.]octane.

112. (withdrawn) The compound of claim 111 which is (2R)-1-(3-benzo[*d*]isoxazol-3-yl-8-azabicyclo[3.2.1]oct-8-yl-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)propan-2-ol.

113. (original) A compound according to claim 1, wherein R_3 is adamantyl.

114. (original) The compound of claim 113 which is (2R)-1-(adamantan-1-ylamino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

115. (withdrawn) A compound according to claim 1, wherein Q is cyclohexyl.

116. (withdrawn) compound of claim 115 which is (2R)-1-(cyclohexylmethyl-amino)-3-(3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy)-propan-2-ol.

117. (withdrawn) A compound according to claim 1, wherein Q is benzimidazolyl.

118. (withdrawn) The compound of claim 117 which is (2R)-1-[(1H-benzimidazol-2-ylmethyl)amino]-3-[3-thieno[2,3-*d*]isoxazol-3-yl-phenoxy]propan-2-ol.

119. (original) A compound according to claim 1, wherein R_3 is 1,2,3,4-tetrahydronaphthyl.

PAGE 10/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

120. (original) The compound of claim 119 which is (2R)-1-(1,2,3,4-tetrahydronaphthalen-1-ylamino)-3-[3-thieno[2,3-d]isoxazol-3-yl)phenoxy]propan-2-ol.

121. (withdrawn) A compound of formula



wherein X is $N(CH_3)$ or O; and

R_1 is H or C_{1-6}alkyl.

122. (withdrawn) A compound of formula



wherein X is $N(CH_3)$ or O;

R_1 is H or C_{1-6}alkyl; and

R_2 is CH_3, F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene.

123. (withdrawn) A method for antagonizing the effects of dopamine at the D_4 receptor comprising administering a compound according to claim 1 to a patient in need thereof.

124. (original) A composition comprising a compound according to claim 1 in admixture with an inert carrier.

125. (original) The composition according to claim 124 wherein said inert carrier is a pharmaceutical carrier.

126. (withdrawn) A method of treating psychoses comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

127. (withdrawn) A method of treating Attention Deficit Hyperactivity Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

128. (withdrawn) A method of treating Obsessive-Compulsive Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

129. (withdrawn) A method of treating Substance Abuse comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

PAGE 11/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

130. (withdrawn) A method of treating Substance Dependence comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

131. (withdrawn) A method of treating Parkinson's Disease comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

132. (withdrawn) A method of treating Parkinsonism comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

133. (withdrawn) A method of treating Tardive Dyskinesia comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

134. (withdrawn) A method of treating Gilles de la Tourette Syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

135. (withdrawn) A method of treating Conduct Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

136. (withdrawn) A method of treating Oppositional Defiant Disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.

137. (currently amended) A method of making a compound of formula I



I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is $N(CH_3)$ or O;

R_1 is OH or C_{1-6} alkoxy;

R_2 is H or C_{1-6} alkyl;

R_3 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl~~, phenyl,~~ or furanyl~~, naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl , cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl~~, and

PAGE 12/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2; and

R_4 is H or C_{1-6} alkyl; ~~or~~

~~R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form 1,4 dioxa 8 aza spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4 tetrahydroisoquinolinyl, 1,2,3,4 tetrahydro β carbolinyl, 4,5,6,7 tetrahydrothienyl[3,2 c]pyridyl, or 8 aza bicyclo[3.2.1.]octane, each of which may be mono or independently di substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O phenyl or $(CH_2)_m$Z,~~

~~Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2 methylenedioxyphenyl, or phenyl, and~~

~~Z, CH(OH)phenyl or O phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and~~

~~m is 0 or 1;~~

comprising the step of coupling a reagent of formula II



II

wherein X and R_2 are as defined in formula I;

with a reagent of formula III



III

PAGE 13/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

wherein R_3 and R_4 are as defined in formula I;

to provide the compound of formula I.

PAGE 14/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

138. (currently amended) A method of making a compound of formula I



I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is $N(CH_3)$ or O;

R_1 is OH or C_{1-6} alkoxy;

R_2 is H or C_{1-6} alkyl;

R_3 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl~~, phenyl,~~ or furanyl, ~~naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl,~~ and

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2; and

R_4 is H or C_{1-6} alkyl; ~~or~~

~~R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form 1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridyl, or 8-aza-bicyclo[3.2.1.]octane, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_m$Z,~~

~~Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and~~

~~Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and~~

~~m is 0 or 1;~~

PAGE 15/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

comprising the step of coupling a compound of formula II



II

wherein X and R_2 are as defined in formula I; and

R_5 is CH_3, CF_3, F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene;

with a reagent of formula III



wherein R_3 and R_4 are as defined in formula I;

to provide the compound of formula I.

139. (currently amended) A method of making a compound of formula I



I

a pharmaceutically acceptable salt or stereoisomer thereof,

wherein

X is $N(CH_3)$ or O;

R_1 is OH or C_{1-6} alkoxy;

R_2 is H or C_{1-6} alkyl;

R_3 is $(CH_2)_n$ Q, $CH_2CH(OH)Q$, $CH(CH_3)Q$, 1,2,3,4-tetrahydronaphthyl, indanyl, or adamantyl, wherein

Q is thienyl~~, phenyl,~~ or furanyl, ~~naphthyl, pyridyl, indolyl, indazolyl, cyclohexyl, 1,2-methylenedioxyphenyl, cyclohexenyl, 1H-pyrazolo[4,3-c]pyridyl,~~ and

Q is optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, $S(O)_2NH_2$, trifluoromethyl, or cyano, and

n is 1 or 2; and

PAGE 16/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08

R_4 is H or C_{1-6} alkyl; ~~or~~

~~R_3 and R_4, together with the nitrogen atom to which R_3 and R_4 are attached, form 1,4-dioxa-8-azo-spiro[4.5]decanyl, piperazinyl, morpholinyl, piperidinyl, pyrrolidinyl, azocanyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydro-β-carbolinyl, 4,5,6,7-tetrahydrothienyl[3,2-c]pyridyl, or 8-aza-bicyclo[3.2.1.]octane, each of which may be mono- or independently di-substituted with halo, C_{1-6} alkyl, C_{1-6} alkoxy, C(O)phenyl, OH, CN, O-phenyl or $(CH_2)_m$Z,~~

~~Z is benzisoxazolyl, indazolyl, benzisothiazolyl, benzothienyl, pyrimidinyl, pyridyl, 1,2-methylenedioxyphenyl, or phenyl, and~~

~~Z, CH(OH)phenyl or O-phenyl are optionally substituted with one or two moieties independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, trifluoromethyl, $S(O)_2NH_2$, or cyano, and~~

~~m is 0 or 1;~~

comprising the step of coupling a reagent of formula II



II

wherein X is as defined in formula I;

with a reagent of formula III



III

wherein R_2, R_3, and R_4 are as defined in formula I;

to provide the compound of formula I.

PAGE 17/18 * RCVD AT 5/20/2005 11:08:33 AM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/25 * DNIS:2730706 * CSID:908 231 2626 * DURATION (mm-ss):05-08